MedTrace Logo

Topical Versus Intravenous Tranexamic Acid in Total Knee Arthroplasty

NCT02323373 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2015-01-14

No results posted yet for this study

Summary

This clinical trial investigated two different routes of administration of tranexamic acid in total knee arthroplasty: topical compared to intravenous.

Conditions

  • Arthrosis

Interventions

DRUG

Tranexamic Acid - topical

Tranexamic acid is an antifibrinolytic agent that decreases perioperative blood loss, because it inhibits fibrinolysis by competing with lysine molecule in coupling sites in fibrinogen. In this study arm, the drug is administered topically on the wound.

DRUG

Placebo

100 ml of saline solution administered with anesthesia during 10 minutes

DRUG

Tranexamic Acid - intravenous

Tranexamic acid is an antifibrinolytic agent that decreases perioperative blood loss, because it inhibits fibrinolysis by competing with lysine molecule in coupling sites in fibrinogen. In this arm, the drug is administered intravenously.

Sponsors & Collaborators

  • Irmandade da Santa Casa de Misericordia de Sao Paulo

    lead OTHER

Principal Investigators

  • Zekcer Ari, MD, PhD · Santa Casa de São Paulo

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2014-11-30
Completion
2014-11-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02323373 on ClinicalTrials.gov